Trump critical of FDA decision to revoke emergency use of drug he has promoted for COVID-19
The U.S. Food and Drug Administration on Monday revoked its emergency use authorization for hydroxychloroquine to treat COVID-19, but quickly came under fire from President Donald Trump, who said only U.S. agencies have failed to grasp its benefit in fighting the coronavirus. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2020 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Revokes Emergency Coronavirus Use of Malaria Drugs
The agency said that a review of some studies showed that the drugs ’ potential benefits in treating Covid-19 did not outweigh the risks. (Source: NYT Health)
Source: NYT Health - June 15, 2020 Category: Consumer Health News Authors: Katie Thomas Tags: Drugs (Pharmaceuticals) Hydroxychloroquine (Drug) Coronavirus (2019-nCoV) Food and Drug Administration Biomedical Advanced Research and Development Authority Trump, Donald J Tests (Medical) Clinical Trials your-feed-healthcare Source Type: news
FDA warns against combination of malaria drug and Gilead's remdesivir
The U.S. Food and Drug Administration on Monday issued a warning to healthcare providers against administering malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences' experimental COVID-19 drug, remdesivir. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2020 Category: Consumer Health News Tags: healthNews Source Type: news
Coronavirus: US withdraws emergency use of hydroxychloroquine
President Trump defends promoting hydroxychloroquine as the FDA says there is no evidence it works. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - June 15, 2020 Category: Consumer Health News Source Type: news
FDA nixes hydroxychloroquine, warns not to take with Gilead's Covid-fighting drug
Regulators on Monday withdrew emergency use authorization of a drug promoted by President Donald Trump for use against Covid-19 and warned that its combination with Gilead Sciences Inc.'s remdesivir could have side effects.
The Food and Drug Administration said a nonclinical laboratory study of Foster City-based Gilead's (NASDQ: GILD) remdesivir, which also has emergency use authorization, with chloroquine or hydroxychloroquine indicated "potential drug interactions." It recommended against administering… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 15, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
